TLSA Tiziana Life Sciences Ltd IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1723069 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 | FY2020*2020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $5.23M | $8.11M | $12.96M | $13.21M | $5.99M |
| Operating income | -$15.79M | -$17.98M | -$14.59M | -$27.37M | -$28.03M |
| Interest expense | $1.77M | $412,000 | $876,000 | — | — |
| Pretax income | -$16.75M | -$17.24M | -$15.40M | -$26.66M | -$28.34M |
| Income tax | -$4.88M | $449,000 | — | -$3.24M | -$2.21M |
| Net income | -$11.86M | -$17.69M | -$15.40M | -$23.42M | -$26.13M |
| EPS (basic) | -0.11 | -0.17 | -0.15 | -0.24 | -0.16 |
| EPS (diluted) | -0.11 | -0.17 | -0.15 | -0.24 | -0.16 |
| Balance sheet | |||||
| Cash & equivalents | $3.72M | $1.18M | $18.12M | $42.19M | $65.82M |
| Current assets | $7.51M | $7.34M | $24.28M | $48.68M | $70.18M |
| PP&E, netmay include right-of-use assets (IFRS) | $16,000 | $10,000 | $17,000 | $17,000 | $3,000 |
| Intangibles | — | — | — | $130,000 | $120,000 |
| Total assets | $11.28M | $12.18M | $26.48M | $48.83M | $70.66M |
| Current liabilities | $7.35M | $6.54M | $6.66M | $7.55M | $7.98M |
| Total liabilities | $7.35M | $6.65M | $6.91M | $7.55M | $8.27M |
| Shareholders' equity | $3.94M | $5.54M | $19.57M | $41.28M | $62.39M |
| Cash flow statement | |||||
| Operating cash flow | -$1.53M | -$15.70M | -$19.61M | -$21.76M | -$11.34M |
| Capital expenditure | $19,000 | — | — | $22,000 | $3,000 |
| Free cash flow | -$1.54M | — | — | -$21.78M | -$11.34M |
| Investing cash flow | -$71,000 | -$1.25M | -$4.00M | $130,000 | -$123,000 |
| Financing cash flow | $4.50M | $40,000 | -$55,000 | -$23,000 | $75.35M |
| Stock-based compensation | $910,000 | $1.73M | -$1.41M | $5.17M | $26,000 |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.